• contact us navContact Us
  • search navSearch
Let's connect

Want to discuss your project or have any questions?

DMPK consultancy services 

DMPK consultancy for drug discovery

We have broad experience collaborating with multidisciplinary drug discovery teams in the pharmaceutical industry, enabling us to integrate seamlessly into your team or function independently as needed. Our consultancy services are available to academia, CROs, biotech and pharmaceutical companies, and life science venture capital funds. We provide support across all stages of drug discovery, from early hit identification to preclinical candidate profiling. This includes human pharmacokinetic (PK) prediction and estimating an effective human dose based on a proposed PK/pharmacodynamic (PD) relationship. 

Scientists discussing a graph in a meeting room

Expert consultancy services for DMPK

DMPK consultancy plays a pivotal role in early-stage drug development, providing valuable expertise in optimising the pharmacokinetic properties of drug candidates. Identifying the ADME characteristics of compounds is crucial for predicting their behaviour in the body. Our DMPK consultants use various in vitro assays, such as liver microsomal stability tests, Caco-2 permeability assays and CYP450 enzyme profiling, to assess how a drug will be absorbed, metabolised and eliminated. They also evaluate plasma protein binding and tissue distribution to help ensure that a compound can reach its intended target in therapeutic concentrations. 


We support your project from early hit identification through preclinical candidate profiling, including human PK prediction and estimation of an efficacious human dose based on a suggested PK/PD relationship. Our goal is to help identify and characterise drug candidates by optimising drug properties, identifying metabolic pathways and understanding potential interactions with other drugs. Our insights can help avoid costly late-stage failures by addressing issues like poor bioavailability, off-target toxicity or undesirable interactions with metabolic enzymes early in the development process. We offer problem-solving solutions using standard high-throughput assays or tailor-made approaches. Our DMPK consultants can also review research proposals or due-diligence packages regarding DMPK and ADME-related risks (e.g., risk of insufficient absorption, exposure, and drug-drug interactions [DDIs]) and offer solutions to further define or de-risk them. 

 
v.1.1.1203